Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line

New Microbiologica

Volumn 33, Issue 2, 2010, Pages 109-115

  Gibellini, Davide ^a   Borderi, Marco ^a   De Crignis, Elisa ^a   Clo, Alberto ^a   Miserocchi, Anna ^a   Viale, Pierluigi ^a   Re, Maria Carla ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

HIV; OPG RANKL; Protease inhibitors

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, HUMAN;

ARTICLE; CELL LINE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; METABOLISM; OSTEOBLAST;

CELL LINE; GENE EXPRESSION REGULATION; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; OSTEOBLASTS; RANK LIGAND;

EID: 77952692939     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. BALDINI G., PONTI C., BORTUL R., NARDUCCI P., GRILL V., MARTELU A.M. (2008). Sparc localizes to the blebs of hobit cells and human primary osteoblasts. J. Cell. Biochem. 104, 2310-2323.
2. BARILLARI G., ENSOLI E. (2002). Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin. Microbiol. Rev. 15, 310-326.
3. BORDERI M., GIBELLINI D., VESCINI E., DE CRIGNIS E., CIMATTI L., BIAGETTI C., TAMPELLINI L., RE M.C. Metabolie bone disease in HIV infection. (2009). AIDS. 23, 1297-1310.
4. BROWN T.T., QAQISH R.B. (2006). Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 20, 2165-2174.
5. COZZOLINO M., VIDAL M., ARCIDIACONO M.V., TEBAS P., YARASHESKI K.E., DUSSO A.S. (2003). HIV-protease inhibitors impair vitamin D bioactivation to 1,25dihydroxyvitamin D. AIDS. 17, 513-520.
6. DE CRIGNIS E., CIMATTI L., BORDERI M., GIBELLINI D., RE M.C. (2008). Bone alterations during HIV infection. New Microbiol. 31, 155-164.
7. Dusso A., VUOAL M., POWDERLY W.G., YARASHESKI K.E., TEBAS P. (2000) Protease inhibitors inhibit in vitro conversion of 25(OH)-vitamin D to 1,25 (OH)2-vitamin D. Antiviral Therapy. 6, 10-18.
8. ELECTRONIC MEDICINES COMPENDIUM, http://emc.medi-cines.org.uk/
9. FAKRUDDIN J.M., LAURENCE J .J. (2003). HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferongamma/RANKL cross-talk. Biol. Chem. 278, 48251-48258.
10. FAUCI A.S. (2003). HIV and AIDS: 20 years of science. Nat. Med. 9, 839-843.
11. GIBELLINI D., BORDERI M., DE CRIGNIS E., CICOLA R., VESCINI E., CAUDARELLA R., CHIODO E., RE M.C. (2007). RANKIVOPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1positive men. J. Med. Virol. 79, 446-1454.
12. GIBELLINI D., DE CRIGNIS E., PONTI C., CIMATTI L., BORDERI M., TSCHON M., GIARDINO R., RE M.C. (2008). HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J. Med. Virol. 80, 1507-1514.
13. HAGGERTY C.M., PITT E., SILICIANO R.F. (2006). The latent reservoir for HIV-1 in resting CD4+ T. cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. Curr. Opin. HTV. AIDS. 1, 62-69.
14. JAIN R.G., LENHARD J.M. (2002). Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J. Biol. Chem. 277, 19247-19250.
15. KONISHI M., TAKAHASHI K., YOSHIMOTO E., UNO K., KASAHARA K., MIKASA K. (2005). Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS. 19, 1240-1241. (Pubitemid 41059272)
16. LEVINE M., MANLEY J.L. (1989). Transcriptional repression of eukaryotic promoters. CeIl. 59, 405-409.
17. LEVY J.A. (2009). HIV pathogenesis: 25 years of progress and persistent challenges. AIDS. 23, 147-160.
18. MALIZIA A.P., COTTER E., CHEW N., POWDERLY W.G, DORAN P.P. (2007). HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res. Hum. Retroviruses. 23:243-250.
19. MARIE P.J. (2008). Transcription factors controlling osteoblastogenesis. Arch. Biochem. Biophys. 473, 201-209.
20. MATSUO K., IRIE N. (2008). Osteoclast-osteoblast communication. Arch. Biochem. Bioph. 473, 201-209.
21. MONDY K., TEBAS P. (2003). Emerging bone problems in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 36, S101-105.
22. MORA S., ZAMPRONI I., CAFAREIXI L., GIACOMET V., ERBA P., ZUCCOTTI G., VIGANÒ A. (2007). Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS. 21, 1129-1135.
23. NACHER M., SERRANO S., GONZALEZ A., HERNANDEZ A., MARINOSO M.L., VILELLA R., HINAREJOS P., DÍEZ A., AUBIA J. (2001). Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS. 15, 2239-2243.
24. RE M.C., VITONE E., BON I., SCHIAVONE P., GIBELLINI D. (2006). Meaning of DNA detection during the follow-up of HIV-I infected patients: a brief review. New Microbiol. 29, 81-8 8.
25. SERRANO S., MARINOSO M.L., SORIANO J.C, RUBIÉS-PRAT J., AUBIA J., COLL J., BOSCH J., DEL RIO L., VILA J., GODAY A. (1995). Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone. 16, 185-191.
26. VAANANEN H.K., LATTALA-LEINONEN T. (2008). Osteoclast lineage and function. Arch. Biochem. Biophys. 8, 473, 132-138.
27. WRIGHT E.J. (2009). Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr. Rev. Musculoskelet. Med. 2, 56-64.